An array of updates surround The Cigna Group (CI). The organization recently declared a quarterly dividend and observed a significant 14% Q1 2025 revenue growth, exceeding Wall Street expectations with a boost in its earnings per share (EPS) guidance. Hedge Funds consider CI among cheap ESG stocks for investment. Further boosting its credibility, analysts from renowned firms, like Truist Securities, Guggenheim, and Barclays, raised the price targets for CI. However, the stock suffered a slight setback with a drop of 6.47% on May 12.
In its strategic shift, CI successfully sold its Medicare businesses to HCSC. The company also recently experienced management changes anticipated to fast-track growth. A unique initiative tying executive pay to patient satisfaction has been introduced, further aligning objectives with patient health outcomes. Additionally, the CEO affirmed the strong Q1 earnings and increased outlook revealing the strength in growth platforms.
Despite losing its oncology leader to The Oncology Institute, CI maintains its glow as a leading healthcare stock.
The Cigna Group CI News Analytics from Mon, 28 Oct 2024 07:00:00 GMT to Sat, 17 May 2025 04:12:37 GMT - Rating 7 - Innovation 2 - Information 8 - Rumor 2
